UBP 302 is primarily used in neuroscience research as a selective antagonist for kainate receptors, specifically targeting the GluK1 subtype. Its application is crucial in studying the role of these receptors in synaptic transmission, plasticity, and neurological disorders such as epilepsy, chronic pain, and neurodegenerative diseases. By blocking GluK1 receptors, UBP 302 helps researchers understand their contribution to excitatory signaling in the brain, providing insights into potential therapeutic targets for conditions involving excessive glutamate activity. Additionally, it is utilized in electrophysiological and pharmacological experiments to dissect the functional differences between various glutamate receptor subtypes.